Latest It Consulting News

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

Alexium International Group Limited posted a 42.2% increase in net loss for FY2025, with revenues down 33.4% due to a soft US mattress market. Despite financial setbacks, the company advanced key technologies and announced leadership changes that could fuel future growth.

Simble Solutions Limited reported a 21.3% revenue decline and a $646,578 net loss for H1 2025, while raising $807,375 to fund strategic growth in renewable energy and AI integration.

CPT Global Limited reported a 12% revenue increase to $23.1 million for FY2025, driven by growth in the Northern Hemisphere segment, while narrowing its net loss to $706,214. The company is strategically pivoting towards larger markets and investing in technology and talent to fuel future growth.

MA Credit Income Trust has closed its Shortfall Offer ahead of schedule after demand exceeded the $190.5 million target, while updating the timetable for its upcoming Entitlement Offer.

Orcoda Limited reported a 33% drop in FY25 revenue to $17.16 million and a net loss of $2.5 million, driven by deferred projects in its Resource & Infrastructure division. Meanwhile, its Transport Technology division posted EBITDA growth, signaling a potential turnaround.

FINEOS Corporation Holdings PLC reports solid half-year growth with rising subscription revenue and improved margins, while navigating currency challenges. The company remains confident in achieving positive free cash flow for FY25 and advancing its AI and cloud strategies.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

FOS Capital reported solid FY25 results, driven by organic growth and key acquisitions that expanded its market footprint and improved profitability. The company’s strategic moves position it well for continued consolidation in the fragmented lighting industry.

XPON Technologies Group Ltd reported a strategic acquisition and a near elimination of EBITDA losses in FY25, signaling a pivot towards sustainable growth in AI marketing technology.